健帆生物(300529) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was CNY 578,901,351.98, representing a 52.79% increase compared to CNY 378,881,893.33 in the same period last year[2] - Net profit attributable to shareholders was CNY 283,305,904.08, up 53.62% from CNY 184,425,240.75 year-on-year[2] - The net profit after deducting non-recurring gains and losses was CNY 273,780,539.71, reflecting a 45.07% increase from CNY 188,722,755.82 in the previous year[2] - Basic and diluted earnings per share were both CNY 0.35, marking a 52.17% increase from CNY 0.23 in the previous year[2] - The total profit for Q1 2021 was ¥334.48 million, a 54.75% increase from ¥216.14 million in Q1 2020, driven by revenue growth[10] - The company's operating income for Q1 2021 was approximately CNY 571.74 million, a 52.8% increase from CNY 374.49 million in the same period last year[28] - The net profit attributable to shareholders was approximately CNY 283.31 million, up 53.6% from CNY 184.43 million year-over-year[27] - The total comprehensive income of approximately CNY 284.19 million for the quarter, compared to CNY 186.08 million in the same period last year, marking a 52.7% increase[30] Cash Flow - The net cash flow from operating activities reached CNY 234,720,147.72, a 56.94% increase compared to CNY 149,559,054.79 in the same quarter last year[2] - Cash flow from operating activities for Q1 2021 was ¥234.72 million, a 56.94% increase from ¥149.56 million in Q1 2020, mainly due to increased sales receipts[13] - Total operating cash inflow reached CNY 595.59 million, up from CNY 391.97 million year-on-year, representing a 52% increase[32] - Cash and cash equivalents at the end of the period amounted to CNY 1,637.12 million, up from CNY 1,075.89 million, showing a 52% increase[33] - The company reported a net increase in cash and cash equivalents of CNY 67.07 million, contrasting with a decrease of CNY 190.84 million in the previous year[33] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,509,098,386.57, an 8.55% increase from CNY 3,216,670,261.94 at the end of the previous year[2] - The total assets of the company as of March 31, 2021, were 3.51 billion yuan, an increase from 3.22 billion yuan at the end of 2020[19] - Total liabilities amounted to CNY 394,053,083.68, reflecting an increase of CNY 1,836,628.97 compared to the previous period[40] - Total liabilities increased to ¥402,170,112.32, compared to ¥392,216,454.71 in the previous period, reflecting a rise of 2.4%[24] - The company reported a significant increase in long-term assets, with total non-current assets reaching 1.40 billion yuan, compared to 1.23 billion yuan at the end of 2020[19] Research and Development - R&D expenses for Q1 2021 totaled ¥20.91 million, a 71.70% increase from ¥12.18 million in Q1 2020, indicating a significant boost in R&D investment[10] - Research and development expenses for Q1 2021 were ¥20,905,465.60, up from ¥12,175,518.59 in Q1 2020, representing an increase of 71.5%[25] - The company reported a focus on innovation with research and development expenses for the quarter being approximately CNY 17.22 million, an increase from CNY 10.21 million in the previous year[28] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 35,231, with the largest shareholder holding 43.90% of the shares[5] - Net assets attributable to shareholders amounted to CNY 3,093,379,229.69, up 10.21% from CNY 2,806,789,690.15 at the end of the previous year[2] - The total equity attributable to shareholders reached ¥3,114,605,173.08, an increase of 10.1% from ¥2,827,126,989.85 at the end of 2020[24] Government Subsidies - The company received government subsidies amounting to CNY 3,632,894.59 during the reporting period[3] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[24]